Sign in
CompletedNo phase

Liver Biomarkers in Anorexia Nervosa

Key facts

Who runs it
Nantes University Hospital
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
43 people enrolled
Started
23 Jun 2023
Ended
27 Jun 2025
Type of study
Observational
Treatments tested
  • Fibroscan
Record updated
17 April 2026

Who can take part

Age
15 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Patient over 15 years old
  • Diagnosis of Restricted Eating Disorders including Anorexia Nervosa according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
  • Admission to the endocrinology, diabetology and nutrition department of the Nantes University Hospital

Who cannot take part

  • Treatment with a drug known to induce fatty liver disease (amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals) unless the dose has been stable for ≥ 3 months
  • Chronic active viral hepatitis
  • Other genetic, autoimmune, toxic or drug-induced hepatitis
  • Hemochromatosis
  • Excessive alcohol consumption (≥ 30 grams per day in men, ≥ 20 grams per day in women)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main goal of the Liver Biomarkers in Anorexia Nervosa (LIBAN) study is to determine the prevalence of liver fibrosis in patient with Anorexia Nervosa.

The group in the trial

  • Non applicable (NA)

    Patients with Anorexia Nervosa hospitalized for malnutrition

    Treatment: Fibroscan

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessment of Liver Damage Using the Fibroscan in Patients With Anorexia Nervosa
Record updated
17 April 2026